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Background: Detection of choroidal inflammation in Vogt-Koyanagi-Harada (VKH) disease is still a challenge.
Progression to sunset glow fundus has been observed despite apparent good clinical control of inflammation.
Indocyanine green angiography (ICGA) permits choroid inflammation detection, though it is invasive, time
consuming, and costly. The purpose of the present study is to report a sign indicative of probable inflammation
on enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT): a localized increase in
choroidal thickness with bulging of the outer retina (‘choroidal bulging’) in patients with VKH disease in the
non-acute uveitic stage.
Findings: This is a retrospective observational study. The choroidal bulging was a particular finding observed
in four eyes of three patients with VKH disease in the non-acute uveitic stage (median disease duration 55.3 ± 40.3 months,
range 10 to 108). This study is part of an ongoing longitudinal study in patients with VKH disease carried out in the
Uveitis Service, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. In all eyes,
the choroidal bulging was identified in the presence of anterior chamber cells and/or on fundus angiographic
(fluorescein and indocyanine green) findings, indicative of disease activity. Changes in the thickness of the choroidal
bulging accompanied the variation in the clinical and angiographic signs of inflammation.
Conclusion: The choroidal bulging is a particular finding detected on EDI-OCT that may indicate ongoing inflammation
in the posterior segment of the eye. This EDI-OCT feature may assist in the treatment-monitoring of patients with
Vogt-Koyanagi-Harada disease in the non-acute uveitic stage.
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Background
Vogt-Koyanagi-Harada (VKH) disease is an autoimmune
disorder, in which the choroid is the main site of
disease-related inflammation in the eye [1]. Detection of
choroidal inflammation is still a challenge, and progres-
sion of VKH disease has been observed despite apparent
good clinical control of inflammation. Indocyanine green
angiography (ICGA) has been used as a sensitive tech-
nique for imaging choroidal inflammation. However, it is* Correspondence: vmsakata@yahoo.com.br
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in any medium, provided the original work is plimited by the fact that it is invasive, time consuming,
and costly. Moreover, recent reports have risen up that
some changes do not represent active lesions but intras-
tromal scars [2].
Newer imaging techniques, such as enhanced depth
imaging optical coherence tomography (EDI-OCT), have
been recently evaluated as an alternative modality of
monitoring treatment effect. In this context, we describe
a unique finding in patients with VKH disease in the
non-acute uveitic stage: the ‘choroidal bulging’, which
seems to be related to active inflammation. This finding
appears as a localized thickening of the choroid that
assumes a convex appearance with consequent bulging
of the adjacent retina, with no nearby obvious retinal
lesion to justify this finding. Although diffuse thickeningn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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inal diseases (including VKH disease), we are not aware
of other conditions that commonly produce choroidal
bulging (i.e., a localized thickening of the choroid) [3,4].
Methods
We retrospectively reviewed sequential clinical and im-
aging data from all eyes noted to have the choroidal
bulging on EDI-OCT performed as part of the follow-up
protocol in an ongoing longitudinal VKH disease study,
which is being conducted at the Uveitis Section, Hospital
das Clínicas, Faculdade de Medicina, Universidade de São
Paulo, São Paulo, Brazil. The study protocol followed the
statements of the Declaration of Helsinki and was ap-
proved by the Universidade de São Paulo Institutional
Review Board. In accordance with the Revised Diagnostic
Criteria for VKH disease [5], incomplete VKH disease was
diagnosed in all cases. The patients included were in the
non-acute uveitic stage, with median disease duration of
55.3 ± 40.3 months (range 10 to 108 months). Fundus
photography was performed using a conventional fundus
camera system (TRC-50X/IMAGEnet, Topcon Inc., Tokyo,
Japan). Fluorescein angiography (FA), ICGA, and EDI-
OCT imaging were performed using Spectralis® HRA +
OCT (Heidelberg Engineering Inc., Heidelberg, Germany).
Results
One area of localized thickening of the choroid that
assumes a convex appearance with consequent bulging of
the adjacent retina (i.e., choroidal bulging) was identified












Location Change ACC Hyperfluores
of OD on
1, M, 65 RE 117 Outer nasal +139 μm
(+74%)
+/2 −
2, F, 54 RE 10 Outer nasal +131 μm
(+139%)
+ ++
LE 10 Outer nasal +138 μm
(+107%)
+ ++
3, F, 53 LE 32 Parafoveal +215 μm
(+74%)
+ +
These characteristics were observed by the time the choroidal bulging was identifie
anterior chamber cells; CB, choroidal bulging; F, female; FA, fluorescein angiography
OD, optic disc; RE, right eye.at least two sequential visits were analyzed. Observation
of the same scan area on EDI-OCT revealed appearance/
disappearance of the choroidal bulging during the period
analyzed. One patient had bilateral involvement and will
be described further. At the time of identification of the
choroidal bulging, all four eyes presented at least one con-
comitant inflammatory sign (anterior chamber cells on
clinical examination and/or optic disc hyperfluorescence
on FA and/or dark dots on ICGA). The changes observed
in the thickness of the choroidal bulging along with the
sequential follow-up EDI-OCT evaluations coincided with
the variation in these inflammatory signs (Table 1).
Case report
A 54-year-old woman with VKH disease diagnosed
3 months ago came for routine evaluation (Patient 2,
Table 1). She was under 40 mg of oral prednisone. Best-
corrected visual acuity was 1.0 in OU; there were no
cells in the anterior chamber in OU. Fundus examin-
ation showed a moderate diffuse depigmentation in OU
(mild fundus) [6]. Angiographic signs of ongoing disease
activity were observed, such as diffuse staining of the
optic disc on FA and numerous, large and coalescent
dark dots at the posterior pole and slightly contiguous to
the temporal rim of the disc on ICGA in both eyes. Sub-
foveal choroidal thickness on EDI-OCT was around nor-
mal ranges (240 μm in right eye (RE) and 193 μm in left
eye (LE)) and no choroidal folds or bulging was observed
at this time (Figures 1a and 2a). Seven months later,
EDI-OCT scan demonstrated a localized thickening of
the choroid in the papillomacular bundle in OUVogt-Koyanagi-Harada disease in non-acute uveitic










+ None Month 137: improvement of CB
(−145 μm), increase in ACC (+),
absence of dark dots (−)
+++ Tapering of oral
prednisone
(15 to 10 mg/day)
Month 17: worsening of CB
(+66 μm), increase in OD
hyperfluorescence (+++),
localized increase of dark dots
+++ Month 17: improvement of CB
(−101 μm), decrease in OD
hyperfluorescence (+/2),




Month 35: disappearance of
CB (−74 μm), maintenance in
OD hyperfluorescence (+),
attenuation of dark dots
d on enhanced-depth imaging spectral optical coherence tomography. ACC,
; FU, follow-up; ICGA, indocyanine green angiography; LE, left eye; M, male;
Figure 1 Choroidal bulging and angiographic findings in the RE of case 2. Absence of abnormalities on EDI-OCT at 3 months of disease in
RE (a). Gradual increase in choroidal thickness (choroidal bulging) in the outer nasal macular sub-field at months 10 (b) and 17 (c) was associated
with gradual increment in optic disc hyperfluorescence on FA and localized appearance of dark dots on ICGA (arrows). Fluctuation in the diffuse
density of dark dots on ICGA was concomitantly observed.
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evident bulging of the outer retina (Figures 1b and 2b).
Biomicroscopy revealed the presence of anterior cham-
ber cells (1+ RE and traces LE). At this time, the patient
was in use of prednisone 15 mg. Topical steroids were
started, and prednisone dose taper was maintained as
part of a dose reduction protocol. At her next visit,
7 months later, choroidal bulging was indeed noticed with
an additional localized increase of 66 μm in choroidalFigure 2 Choroidal bulging and angiographic findings in the LE of ca
in LE. Focal changes (increase and decrease) in choroidal thickness in the o
with the changes observed in the optic disc hyperfluorescence on FA as wthickening in the RE and diminishment in the LE
(−101 μm) (Figures 1c and 2c). FA and ICGA changes
followed the increase in the choroidal bulging in the RE:
on FA, optic disc leakage became evident and more
intense, and on ICGA, two dark dots could be clearly
delineated at the exact place of the choroidal bulging
(Figure 1c, arrows). In the LE, optic disc leakage became
less intense on FA, and localized dark dots persisted
on ICGA at choroidal bulging location, though morese 2. (a) Absence of abnormalities on EDI-OCT at 3 months of disease
uter nasal macular sub-field at months (b) 10 and (c) 17, in agreement
ell as in the localized (arrows) dark dots on ICGA.
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ior chamber were still observed in OU. Oral prednisone
was maintained at 10 mg/day.
Discussion
In VKH disease, detection of choroiditis is still a challenge.
Thus, newer parameters to detect posterior segment
inflammation and to assist the treatment process are
needed. Herein, we describe the choroidal bulging, a
transient finding identified on EDI-OCT in patients
with VKH disease in the non-acute uveitic stage. The
choroidal bulging is characterized by a localized thick-
ening of the choroidal compartment with consequent
bulging of the RPE/Bruch reflective complex anteriorly,
without an associated retinal thickening or any obvious
nearby retinal lesion to justify this finding. Signs of well-
known ongoing disease-related inflammation/activity
were concomitantly observed in all four eyes presenting
choroidal bulging, and fluctuation of this inflammatory
signs was followed by changes in the choroidal bulging.
Diffuse thickening of the choroid has already been
described in the early and convalescent/chronic stages of
VKH [3,4], and it was suggested to represent a sign of dis-
ease activity [3,4]. Nevertheless, as previously described,
progressive choroidal thinning related to disease duration
occurs, and diffuse thickening during disease exacerbation
in the non-acute uveitic stage of the disease may be subtle
and difficult to detect [4,7]. Thus, the localized thickening
of the choroid, the choroidal bulging, may represent a
new sign indicative of posterior segment inflammation in
a non-invasive manner.
Localized choroidal thickening has already been descri-
bed in patients with ocular toxoplasmosis or choroidal
tumors [8,9]; however, different from the choroidal bulging
observed in this series of patients with VKH disease, an as-
sociated retinal or choroidal lesion was invariably observed
in these scenarios on clinical exam (i.e., fundoscopy).
Choroidal bulging could be correlated to choroidal
folds, despite the fact that these are multiple and de-
scribed at the acute phase of the disease [10]. Choroidal
folds or striations have been described as undulations
and bumps on the surface of the retinal pigment epithe-
lium [10]. Choroidal bulging is a transient finding, as
well, but localized, unique, and observed in the non-
acute uveitic stage of the disease. It is probably related to
posterior-segment active inflammation once it was obser-
ved concomitantly to other posterior inflammatory signs.
It is important to emphasize that simultaneous obser-
vation of EDI-OCT and ICGA shows transient dark dots
at the exact location of the choroidal bulging. Actually,
ICGA changes anticipated choroidal bulging detection
on EDI-OCT in all cases. This truly does sound logical
since bulging probably represents the accumulation of
inflammatory elements/fluid associated to the presenceof transient granulomas, which usually take some time to
build up [10]. Indeed, choroidal bulging dynamism (ap-
pearance/disappearance) occurred in a faster way when
compared to the distribution of dark dots on ICGA.
Therefore, the new EDI-OCT sign described here in
the non-acute uveitic phase of the VKH disease does not
substitute ICGA signs, but complement subclinical pos-
terior segment inflammatory evaluation. Given that chor-
oidal bulging has a dynamic nature, a histopathologic
study would hardly be available. In addition, EDI-OCT is
a non-invasive examination and can be easily performed
when compared to ICGA, which is frequently unavailable
in some centers. Further studies evaluating its specificity
and sensitivity should be carried out.
In summary, we describe a novel EDI-OCT finding
called ‘choroidal bulging’ in patients with VKH disease
in the non-acute uveitic stage, who presented other
clinical and/or angiographic sign of disease-related in-
flammation. We propose that this finding, which is easily
and non-invasively identified through serial EDI-OCT
evaluations, may help monitor posterior segment disease
activity in patients with VKH disease in the non-acute
uveitic stage.
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